Navigation Links
Breakthrough Microarray-based Technology for the Study of Cancer

A new development in the analysis of cancer has been announced by Agilent Technologies. The company has reported an innovative method that enables the rapid advance of microarray-based comparative genomic studies in cancer. According to the report published in the December 24, 2004 issue of the Proceedings of the National Academy of Science (PNAS) in collaboration with the National Human Genome Research Institute, Agilent has developed a specialised microarray platform that uses total genomic DNA to overcome several scientific hurdles that previously impeded comparative genomic studies in cancer.

Chromosomal changes in cancer can be studied using Comparative genomic hybridization (CGH), which undergoes dramatic chromosomal changes, including loss, duplication and the translocation of DNA from one chromosome to another, as cancer develops. Understanding these changes is key to understanding cancer progression as well as developing possible therapies and prognostic and diagnostic tools. "Genomic alterations leading to changes in the number of gene copies present in cells are important events in the genesis and progression of cancer," said Michael Bittner of the Translational Genomics Research Institute. "Agilent has now taken array-CGH experiments into a new realm of resolution, sensitivity, and reproducibility that allows reliable detection of alterations at the scale of individual genes and even introns and exons. This advancement, along with the possibility it provides to correlate genomic copy alterations with mRNA abundance and protein abundance, is going to incite a huge body of experimentation and publication among the cancer research community." In the past, comparative genomic hybridization was performed through the optical imaging of whole chromosomes, a technique with limited sensitivity, resolution, quantification and throughput. Efforts in recent years to use microarrays to overcome these limitations have been hampered by inadequate sensitivity, sp ecificity and flexibility of the microarray platforms. As detailed in the PNAS paper, Agilent's breakthrough is founded on the modification of its gene-expression profiling microarray technology to improve its utility for DNA analysis applications. This new platform provides high sensitivity, enabling CGH researchers to reliably identify the single copy deletions in chromosomes that have been the most difficult to detect. Additionally, the technology allows for the use of total genomic DNA to detect chromosomal changes across the entire genome. The Platform enables amplification or non-amplification of total genomic DNA in studies of the whole genome, providing better ease of use and improved experimental design.
'"/>

Source:OBBeC


Related biology news :

1. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
2. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
3. Breakthrough isolating embryo-quality stem cells from blood
4. Breakthrough System for Understanding Ocean Plant Life Announced
5. Breakthrough: Scientists create worlds tiniest organic particles
6. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
7. Sciences Breakthrough of the Year: Watching evolution in action
8. Breakthrough for stem cell research
9. Breakthrough in understanding type-2 diabetes as key genes identified
10. Breakthrough vaccine to treat chemo-resistant ovarian cancer
11. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/12/2017)... PORTLAND, Oregon and PUNE, India , January 12, 2017 ... Technology Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology ... CAGR of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/4/2017)... 4, 2017  For the thousands of attendees at this year,s International ... connected health and biometric measurement devices and services, will be featuring its ... display in A&D Medical,s special CES Exhibit Suite , the new ... of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... MILPITAS, Calif. , Jan. 17, 2017 /PRNewswire/ ... today announced that it has initiated a global ... PTG-100, an oral peptide that targets alpha4beta7 integrin. ... design study is to evaluate the safety/tolerability and ... colitis patients with moderate to severe active disease. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of New Jersey ... appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for its ... of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA located ...
(Date:1/16/2017)... ... January 16, 2017 , ... Attagene , a ... the U.S. Small Business Administration. The Tibbetts Award honors the Small Business ... […] and are considered the best of the best from the thousands of ...
(Date:1/14/2017)... ... January 14, 2017 , ... ... providing complete end-to-end genome assemblies to researchers around the globe. Long considered ... obstacle in answering a wide range of scientific questions. The announcement was ...
Breaking Biology Technology: